Immunological Response after Therapeutic Vaccination with WT1 mRNA-loaded Dendritic Cells in End-stage Endometrial Carcinoma

WT1

WT1

CONTACT US

Summary

The study investigated whether WT1 immunotherapy may present an attractive treatment option. for patients with uterine cancer. This is the first patient with a WT1-positive endometrial carcinoma, to receive immunotherapy with WT1-RNA-loaded dendritic cells, resulting in a vaccine-specific T cell response.

Patients characteristics

A 45 years old was diagnosed with stage IV Serous Endometrial Cancer. Underwent 3 cycles of Chemotherapy, underwent interval debulking surgery with no residual tumor.

Methodology

• Patients underwent leukapheresis to obtain peripheral blood mononuclear cells.
• For each vaccine PBMC were thawed and seeded in culture flasks, on average 1×109 PBMCs were cultured every vaccination
• After adherence, monocytes were differentiated to immature DC, in the presence of recombinant IL-4 and GM-CSF
• On day 6, imDC were electroporated with WT1-RNA
• Electroporated DCs were put back in culture in the presence of TNF- and IL-1
• On day 7, mDC-WT1-RNA was harvested, resuspended in DPBS with 2.5% human serum albumin.

Treatment

The vaccine was administered intradermally (ID) in the patient’s groin 1 injection per week for 4-8 weeks. Before and after injection, the patient applied Imiquimod cream at the site of injection.

Results

• At the start of the vaccination, she was no complaint. Her Karnofsky Performance Scale (KPS) was 60 with a general health and quality of life estimation of 3 at a scale ranging from 1(very bad) to 7 (excellent) • After 2nd vaccination, indicated her general health and QoL estimation of 4 and tumor marker started to decrease and WT1-specific T-cells increased 2.5 fold.
• After 3rd vaccination, she showed more dyspnea, KPS was 50 and general health and QoL was again 3.
• No vaccine-related toxicities were observed.
• The treatment was feasible and there were no treatment-related side-effects.

Conclusion

This is the first patient with a WT1-positive endometrial carcinoma, to receive immunotherapy with WT1-RNA-loaded dendritic cells, resulting in a vaccine-specific T cell response.

Article Reference link: click here

Scientific article publishing date: 12/1/2010

Immucura identifier BSC21_315EN

ALL SCIENTIFIC PAPERS
CONTACT US